New mesothelioma research is being performed at The Netherlands Cancer Institute. The researchers are looking at new combinations of medications to be used on patients that have mesothelioma with BAP1 genetic mutations. More than half of patients with mesothelioma have changes in the BAP1 tumor suppressor gene. When the BAP1[…]
Novel Treatments & Drugs
Using MicroRNA as a Biomarker to Diagnose Mesothelioma
The early diagnosis and treatment of mesothelioma is critical for extending survival in patients. Researchers in Italy may have found a helpful biomarker to catch mesothelioma earlier, up to five years before a clinical diagnosis. This is helpful because once mesothelioma is diagnosed, it is hard to treat due to[…]
Cytokine Factories to Treat Pleural and Peritoneal Mesothelioma
A new study from Rice University in Houston is showing promising results for mesothelioma. It utilizes the immune system to fight cancer cells. The protein that is being studied is interleukin 2 (IL2), which is a protein that regulates white blood cells through the use of cytokines, a cell signal[…]
Opdivo and Yervoy After Mesothelioma Surgery Improves Survival
There might be more options for treating mesothelioma. A study looked at the combination of Opdivo and Yervoy after surgery. The study was performed at the Hyogo College of Medicine in Japan. Opdivo and Yervoy, which were recently approved for the treatment of mesothelioma, improved survival when administered after surgery.[…]
Carbon Ion Radiation Therapy for Mesothelioma
A specific type of radiation could be useful for the treatment of mesothelioma. Carbon-ion beam irradiation along with the chemotherapy drug cisplatin could potentially stop the growth of pleural mesothelioma tumors. Research was conducted at a carbon ion center in Chiba, Japan and results have been published to the American[…]
A Treatment Involving Checkpoint Inhibitors Before Surgery is Showing Promising Results for Mesothelioma
Immunotherapy before aggressive surgery shows great promise for pleural mesothelioma. The combination has shown that it can improve survival for a group of patients with pleural mesothelioma in a phase II study at Baylor College of Medicine. The treatment uses two immune checkpoint inhibitors, durvalumab and tremelimumab. The two drugs[…]
Gavo-Cel Moving to Phase II Trial for Mesothelioma
A study looking at T-cell therapy for mesothelioma is going to phase II of the clinical trial process. Researchers are trying to find out how effective the treatment is when combined with an approved immunotherapy combination. Researchers are looking at the relationship between gavocabtagene autoleucel (gavo-cel) with the combination of[…]
Pleural Mesothelioma and Brain Metastasis
When people are diagnosed with mesothelioma, it is common for the disease to spread. This occurs in around 60 percent of people, but it does not usually spread to the brain. Researchers in Great Britain believe doctors should be focusing on cerebral metastasis in mesothelioma patients in addition to other[…]
Enzyme and Chemotherapy Combination for Mesothelioma
Pleural mesothelioma sufferers could improve their survival by as much as 30 percent when treated with the latest cancer enzyme and chemotherapy. In a recent study known as ATOMIC Meso, ADI-PEG 20 showed effectiveness when used for sarcomatoid and biphasic mesothelioma, the two most resistive to treatment. The enzyme is[…]
STAR-101 Could Make CAR T-Cell Therapy More Effective for Mesothelioma Patients
Early next year, a new clinical trial will be conducted to test an immunotherapy treatment that has a new and unique delivery system. The study will be conducted at the University of Pennsylvania. The Food and Drug Administration gave orphan drug status to SynKIR-110, a CAR T-cell therapy utilized for[…]
